AVAC, Health GAP, Knowledge Ecology International (KEI), and Treatment Action Group (TAG) strongly condemn the Trump Administration’s decision to halt funding to the World Health Organization (WHO) in the midst of the urgent COVID-19 global health crisis.
Treatment Action Group (TAG) celebrates publication of the General Comment on “the human right of everyone to participate in and to enjoy the benefits of scientific progress and its applications” (the right to science), and calls the attention of grassroots activists and global civil society working on health to this landmark document.
This policy brief discusses the impact of underfunding TB research led by U.S. government agencies. The brief explores several prospective opportunities for TB R&D that would be made possible with increased funding, with recommendations on where policymakers and appropriators can make key investments to U.S. government agencies to advance crucial science on TB diagnostics, treatments, and vaccines.
Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.
On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).
Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of…
We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.
Treatment Action Group welcomes the flurry of tuberculosis (TB) data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). This statement includes a summary of major findings, TAG’s take on them, and a more detailed overview of key findings.
Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.